A new wave of concern is building around one of the most celebrated advances in modern medicine. GLP-1 weight-loss drugs, hailed for their ability to curb appetite and drive significant reductions in body weight, are now drawing scrutiny from clinical psychologists and eating-disorder specialists who warn that the same mechanisms making them effective could also make them dangerous for some patients.
The concern comes as a new report indicates that the global incidence of anorexia nervosa and bulimia nervosa rose by 71% between 1990 and 2023, underscoring a broader and increasingly urgent public health challenge. The findings arrive at a moment when GLP-1 therapies are being prescribed at scale across wealthy and middle-income markets, often with limited visibility into patients' psychiatric histories, body-image concerns or prior disordered eating behaviors.
Appetite and Risk
GLP-1 drugs, including widely used obesity treatments, work by slowing gastric emptying and reducing hunger signals in the brain. For many patients, that effect is precisely the point: fewer cravings, smaller meals and sustained weight loss. But clinicians caution that in people with a history of restrictive eating, compulsive exercise, purging or obsessive calorie control, the drugs may reinforce harmful patterns rather than correct them.
That risk is not hypothetical. Eating-disorder specialists say the cultural appeal of rapid weight loss can blur the line between medically supervised treatment and self-destructive thinness-seeking. In patients already vulnerable to body dysmorphia or perfectionism, a medication that suppresses appetite may be interpreted not as a therapeutic tool but as permission to intensify restriction. The result, experts warn, can be a relapse or a new onset of disordered eating.
The issue is especially sensitive because GLP-1s have become a mainstream phenomenon far beyond endocrinology and obesity clinics. Social media has amplified stories of dramatic transformations, while celebrities, influencers and wellness entrepreneurs have helped normalize the drugs as a fast track to a slimmer body. That visibility may increase demand among people who are not medically appropriate candidates, including adolescents and young adults, groups already at elevated risk for eating disorders.
Screening Gaps Widen
The rise in eating disorders also exposes a structural weakness in the way weight-loss medicine is delivered. In many settings, prescribing is moving faster than psychiatric screening. Clinicians may ask about diabetes, cardiovascular risk and body mass index, but not always about past anorexia, bulimia, binge-purge cycles or trauma-related eating behavior. That omission could leave high-risk patients exposed to treatment that worsens psychological distress.
Experts say the answer is not to abandon GLP-1s, which remain among the most important biotech breakthroughs of the decade, but to use them with greater caution. That means more rigorous pre-prescription screening, closer follow-up, and coordination between primary-care doctors, obesity specialists and mental-health professionals. It also means recognizing that weight loss is not always a neutral outcome: in some patients, it can become a trigger, a reinforcement loop or a marker of worsening illness.
The broader public-health context is sobering. Eating disorders are among the deadliest psychiatric conditions, with serious medical complications ranging from malnutrition and electrolyte imbalance to cardiac issues and suicide risk. A 71% increase in incidence over more than three decades suggests that the underlying drivers—social pressure, digital body ideals, stress, access to care and diagnostic awareness—are intensifying rather than easing.
A Treatment Paradox
The GLP-1 boom has created a treatment paradox. On one hand, these drugs offer real benefits for patients with obesity, type 2 diabetes and related metabolic disease. On the other, they may amplify a cultural fixation on thinness that can be psychologically corrosive. That tension is now forcing regulators, prescribers and researchers to confront a difficult question: how do you preserve the medical value of a breakthrough therapy while guarding against misuse in a population already under strain?
For now, the answer appears to lie in tighter clinical guardrails rather than alarm. But the warning from psychologists is clear. As GLP-1 use expands globally, the medical system will need to watch not only waistlines and blood sugar, but also the mental-health consequences of appetite suppression. In a world already seeing a steep rise in anorexia and bulimia, that may prove to be one of the most important safety questions of the obesity-drug era.